- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04469829
Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A prospective, non-randomized controlled open trial in psoriasis patients with metabolic syndrome was conducted between January 2019 and May 2020. Inclusion criteria were age ≥ 18 years, being affected by moderate to severe chronic plaque psoriasis and concomitant metabolic syndrome and being candidate to systemic treatment with methotrexate or secukinumab according to the Italian guideline for psoriasis. Psoriasis was diagnosed on clinical base, and it was classified as moderate to severe if PASI ≥ 10, Investigator Global Assessment (IGA) score≥ 3 and/or Dermatology Life Quality Index ≥ 10%. Metabolic syndrome was diagnosed according to criteria of the National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) and The American Heart Association and the National Heart, Lung, and Blood Institute (AHA/NHLB).3 In particular, metabolic syndrome was confirmed in presence of at least three of the following components: abdominal obesity (waist circumference ≥ 102 cm for men or ≥ 88 cm for women), triglycerides ≥ 150 mg/dL, HDL cholesterol ≤ 40 mg/dL for men or 50 mg/dL for women, systolic/diastolic blood pressure ≥ 130/85 mmHg or receiving drug treatment, and fasting plasma glucose ≥ 100 mg/dL. Exclusion criteria were being affected by psoriatic arthritis, pregnancy, breast feeding, having initiated a systemic treatment for psoriasis in the previous 3 months and having a clinical condition that could affect the metabolic parameters other than metabolic syndrome. After having signed the informed consent for the participation in the study, eligible patients were consecutively assigned in a 1:1 ratio to secukinumab (standard dose) or methotrexate 15 mg/week by subcutaneous administration and folic acid supplementation 5 mg given 24 hours after methotrexate. The primary endpoint was investigating any variation in waist circumference, body mass index (BMI), blood pressure, fasting glucose, total cholesterol, low density lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol, triglycerides, aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine levels at month-6. Any other adverse events related to the treatments and the proportion of patients who discontinued the treatment because of adverse reactions were also reported. The secondary endpoints were assessing the PASI 75 and PASI 90 proportion of responders in the two groups at 6 and 12 months follow-up. Clinical and laboratory data were evaluated at the baseline and every 3 months up to month 12.
Statistical Methods A descriptive statistic was conducted using proportions for categorical and mean and standard deviation (SD) for quantitative variables. The categorical variables were compared between the groups using the chi-squared test, while the quantitative variables were compared using the Student's T test. Variations in waist circumference, BMI, blood pressure, fasting glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, AST, ALT, creatinine levels between baseline and month-6 or 12 were assessed by paired t-test in patient receiving methotrexate or secukinumab, respectively. PASI 75 and PASI 90 proportion of responders at month -6 or 12 in the two cohorts' were compared by the chi-squared test. The normal distribution of data was confirmed using the one-sample Kolmogorov-Smirnov Test. A value of p< 0.05 was considered statistically significant. Statistical analysis was performed using the STATA (version 13 StataCorp, College Station, TX, U.S.A.).
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Paolo Gisondi, MD
- Phone Number: 0039 045 8122546
- Email: paolo.gisondi@univr.it
Study Locations
-
-
-
Verona, Italy, 37126
- University of Verona
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age ≥ 18 years
- being affected by moderate to severe chronic plaque psoriasis and concomitant metabolic syndrome
- being candidate to systemic treatment with methotrexate or secukinumab according to the Italian guideline for psoriasis
Exclusion Criteria:
- being affected by psoriatic arthritis, pregnancy, breast feeding,
- having initiated a systemic treatment for psoriasis in the previous 3 months and having a clinical condition that could affect the metabolic parameters other than metabolic syndrome.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: secukinumab
patients with psoriasis and metabolic syndrome candidate for treatment with secukinumab standard doses
|
standard doses of secukinumab for psoriasis
|
ACTIVE_COMPARATOR: methotrexate
patients with psoriasis and metabolic syndrome candidate for treatment with methotrexate dosed 15 mg/week
|
Methotrexate 15 mg/week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in waist circumference at month 12
Time Frame: 12 month
|
Changes in waist circumference at month 12
|
12 month
|
Changes in BMI at month 12
Time Frame: 12 month
|
Changes in BMI at month 12
|
12 month
|
Changes in blood pressure at month 12
Time Frame: 12 month
|
Changes in blood pressure at month 12
|
12 month
|
Changes in fasting glucose at month 12
Time Frame: 12 month
|
Changes in fasting glucose at month 12
|
12 month
|
Changes in total cholesterol at month 12
Time Frame: 12 month
|
Changes in total cholesterol at month 12
|
12 month
|
Changes in LDL cholesterol at month 12
Time Frame: 12 month
|
Changes in LDL cholesterol at month 12
|
12 month
|
changes in (HDL)-cholesterol at month 12
Time Frame: 12 month
|
changes in (HDL)-cholesterol at month 12
|
12 month
|
Changes in triglycerides at month 12
Time Frame: 12 month
|
Changes in triglycerides at month 12
|
12 month
|
Changes in AST at month 12
Time Frame: month 12
|
Changes in AST at month 12
|
month 12
|
Changes in ALT at month 12
Time Frame: month 12
|
Changes in ALT at month 12
|
month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PASI75 and PASI90
Time Frame: 6 and 12 months
|
assessing the PASI 75 and PASI 90 proportion of responders in the two groups at 6 and 12 months follow-up
|
6 and 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse reactions
Time Frame: 6 and 12 months
|
other adverse events related to the treatments and the proportion of patients who discontinued the treatment because of adverse reactions
|
6 and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paolo Gisondi, MD, Universita di Verona
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Skin Diseases
- Disease
- Skin Diseases, Papulosquamous
- Insulin Resistance
- Hyperinsulinism
- Syndrome
- Psoriasis
- Metabolic Syndrome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
Other Study ID Numbers
- Gisondi5
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Secukinumab
-
Novartis PharmaceuticalsRecruiting
-
Technical University of MunichNovartisCompletedPyoderma GangrenosumGermany
-
Novartis PharmaceuticalsCompletedPlaque PsoriasisThailand
-
Novartis PharmaceuticalsCompletedPlaque PsoriasisUnited States
-
University of Erlangen-Nürnberg Medical SchoolActive, not recruiting
-
Novartis PharmaceuticalsCompletedPsoriatic Arthritis | Axial SpondyloarthritisSpain
-
Novartis PharmaceuticalsCompletedPsoriasisUnited States
-
Saakshi KhattriCompleted
-
Novartis PharmaceuticalsCompletedStudy of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.Psoriatic ArthritisChina